title: Bone health in adults treated with endocrine therapy for early breast or prostate cancer.
abstract: Bone is a hormonally responsive organ. Sex hormones and calcium regulating hormones, including parathyroid hormone, 1-25 dihydroxy vitamin D, and calcitonin, have effects on bone resorption and bone deposition. These hormones affect both bone quality and bone quantity. The sex hormone estrogen inhibits bone resorption, and estrogen therapy has been developed to prevent and treat osteoporosis. Androgens are an important source of estrogen through the action of the enzyme aromatase and may themselves stimulate bone formation. Hence, the sex steroids play a role in bone metabolism. Breast cancer and prostate cancer are frequently hormonally responsive and may be treated with antiestrogens or antiandrogens respectfully. In addition, chemotherapy and supportive medications may alter the patient's endocrine system. In general, the suppression of sex hormones has a predictable affect on bone health, as seen by loss of bone mineral density and increased risk of fragility fractures. The bone toxicity of cancer-directed endocrine therapy can be mitigated through screening, counseling on optimization of calcium and vitamin D intake, exercise, and other lifestyle/behavioral actions, as well as the use of medications when the fracture risk is high. Maintaining bone health in patients who are treated with endocrine therapy for breast and prostate cancer is the focus of this review.
authors.affiliation: From the Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI 5848.
authors.forename: Catherine H
authors.initials: CH
authors.lastname: Van Poznak
mesh_terms: D000328:Adult; D000367:Age Factors; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D001851:Bone Diseases, Metabolic / Q000150:complications / Q000209:etiology / Q000473:pathology / Q000628:therapy; D001842:Bone and Bones / Q000187:drug effects* / Q000473:pathology; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D018931:Antineoplastic Agents, Hormonal